Fig. 4

SMOX and GABBR2 are regulated by transitioning peaks in GIC. a Venn diagrams show the epigenetically upregulated genes newly identified in GIC classified in subgroups taking into account feasibility of molecular validation or suitability for clinical application. b Venn diagrams show the epigenetically downregulated genes newly identified in GIC classified in subgroups taking into account feasibility of molecular validation or suitability for clinical application. c Representative images of SMOX protein expression (green) in iNSC and GIC from patient 52. Nuclei are counterstained with DAPI. Scale bar: 100 µm. Quantification of results is shown as Mean Fluorescence Intensity (MFI) standardised by the number of nuclei for three patients. One-way ANOVA test. *p value < 0.05, **p value < 0.01, ***p value < 0.001, ****p value < 0.0001. d Representative bright-field images show wound healing assay in GIC19 cells treated for 24 h with 10 µM of SMOX inhibitor MD72527. Quantification of results is expressed in wound area at 24 h standardised on t0 for GIC from two patients. Experiments have been performed three times. One-way ANOVA test. *p value < 0.05, **p value < 0.01, ***p value < 0.001. e Invasion assay quantification of results expressed in fold change of the average number of nuclei per image field of GIC from patients 19 and 61 treated with 10 µM of SMOX inhibitor MDL72527 standardised on the vehicle. Experiments have been performed three times. One-way ANOVA test. *p value < 0.05, **p value < 0.01, ***p value < 0.001. f Representative bright-field images show wound healing assay in GIC19 cells treated for 24 h with 100 µM of GABBR2 agonist Baclofen or 200 µM of GABBR2 antagonist CGP36742. Quantification of results is expressed in wound area at 24 h standardised on t0 for GIC from two patients. Experiments have been repeated three independent times. One-way ANOVA test. *p value < 0.05, **p value < 0.01, ***p value < 0.001. g Invasion assay quantification of results expressed in fold change of the average number of nuclei per image field of GIC from patients 19 and 61 treated with 100 µM of GABBR2 agonist Baclofen or 200 µM of GABBR2 antagonist CGP36742 standardised on the vehicle. Experiments have been repeated three independent times. One-way ANOVA test. *p value < 0.05, **p value < 0.01, ***p value < 0.001